Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Kaftrio

    - PMLiVE

    Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE

    The rare inherited disease affects approximately 11,000 people in the UK

    - PMLiVE

    Vertex Pharmaceuticals’ cystic fibrosis therapy Alyftrek granted EC approval

    The rare inherited disease affects more than 109,000 people worldwide

    - PMLiVE

    MHRA approves Bavarian Nordic’s chikungunya vaccine Vimkunya

    Approximately 620,000 cases of the mosquito-borne viral disease were reported worldwide in 2024

    - PMLiVE

    Vertex’s triple combination cystic fibrosis therapy Alyftrek approved by MHRA

    Over 11,000 people in the UK are affected by the rare genetic disease

    - PMLiVE

    NICE approves Vertex’s Casgevy one-time gene therapy for sickle cell disease

    About 15,000 people in England are living with the inherited blood disorder

    - PMLiVE

    MHRA urges companies to prepare for Windsor Framework for medicines

    The new UK-wide arrangements for medicines will come into effect on 1 January 2025

    - PMLiVE

    Ipsen’s Iqirvo approved by MHRA to treat primary biliary cholangitis in adults

    Approximately 25,000 people in the UK are affected by the rare liver disease

    - PMLiVE

    FDA grants rare paediatric disease designation to Enterprise’s cystic fibrosis candidate

    The genetic disease is estimated to affect more than 100,000 people globally

    - PMLiVE

    NICE recommends Vertex/CRISPR’s Casgevy gene therapy for beta thalassaemia

    An estimated 460 patients in England with severe cases of the blood disorder could be eligible for Casgevy

    - PMLiVE

    Pfizer/BioNTech’s Omicron JN.1-adapted COVID-19 vaccine approved by MHRA

    The UK regulator has approved four versions of the updated vaccine for adults and children from infancy

    - PMLiVE

    Novo Nordisk’s semaglutide approved by MHRA to prevent cardiovascular event risk

    Approximately 7.6 million people are living with heart and circulatory diseases in the UK

    - PMLiVE

    MHRA approves first generic raltegravir medicines to treat HIV in adults and children

    More than 91,000 people in England were diagnosed with HIV and accessing care in 2022

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links